

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter [with the proviso that said promoter is not a target-specific promoter that targets bacteria], wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein one of said first and second arms is proximal to said trans-acting ribozyme, and the other of said first and second arms is longer than the corresponding arm of a pCLIP cassette.

Claims 2-3 (Cancelled)

4. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said nucleotide sequence encodes a pChop cassette.

5. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said nucleotide sequence encodes a pSnip cassette.

6. (Cancelled)

7. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said recombinant nucleic acid comprises an origin of replication.

Claims 8-9 (Cancelled)

10. (Currently Amended) A cell containing a recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter [with the proviso that said promoter is not a target-specific promoter that targets bacteria], wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein one of said first and second arms is proximal to said trans-acting ribozyme, and the other of said first and second arms is longer than the corresponding arm of a pCLIP cassette.

11. (Cancelled)

12. (Currently Amended) A virion comprising a recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter [with the proviso that said promoter is not a target-specific promoter that targets bacteria], wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein one of said first and second arms is proximal to said trans-acting ribozyme, and the other of said first and second arms is longer than the corresponding arm of a pCLIP cassette.

Claims 13-16 (Cancelled)

17. (Currently Amended) A liposome composition comprising a recombinant nucleic acid comprising a nucleotide sequence encoding an autocatalytically cleaving ribozyme and a trans-acting ribozyme, wherein said nucleotide sequence is operably linked to a tissue-specific promoter [with the proviso that said promoter is not a target-specific promoter that targets bacteria], wherein said autocatalytically cleaving ribozyme comprises a first arm of complementary sequence and a second arm of complementary sequence, wherein the cleavage site of said autocatalytically cleaving ribozyme is located between said first and second arms, and wherein one of said first and second arms is proximal to said trans-acting ribozyme, and the other of said first and second arms is longer than the corresponding arm of a pCLIP cassette.

18. (Cancelled)

19. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said recombinant nucleic acid encodes more than one trans-acting ribozyme.

20. (Previously Presented) The recombinant nucleic acid of claim 19, wherein the trans-acting ribozymes are targeted to different sites on the same target-RNA.

21. (Previously Presented) The recombinant nucleic acid of claim 19, wherein the trans-acting ribozymes are targeted to different target-RNAs.

22. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said recombinant nucleic acid encodes more than one ribozyme cassette.

23. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said recombinant nucleic acid encodes at least two different ribozymes cassettes.

24. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said recombinant nucleic acid encodes more than one copy of a ribozyme cassette.

25. (Cancelled)

26. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said trans-acting ribozyme is targeted to a transcript selected from the group consisting of: pol II, HBV, pol III, RB, IGF1, SH, pol I, HPV, C3, C9, B2, Tel, TGF.beta., CAT, PpaR.alpha., p4501E1, AR, and SF1 transcripts.

Claims 27-34 (Cancelled)

35. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said nucleotide sequence encodes a hairpin loop.

36. (Previously Presented) The recombinant nucleic acid of claim 1, wherein said nucleotide sequence encodes multiple ribozyme cassettes linked together by at least 4 nucleotides.

37. (Cancelled)

38. (Currently Amended) The recombinant nucleic acid of claim 1, [wherein said nucleotide sequence is operably linked to a tissue-specific promoter,] wherein said tissue-specific promoter is a K4 promoter, K7 promoter, K13 promoter or albumin promoter.